Wt Creasman

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. ncbi Breast cancer: the role of hormone therapy
    William T Creasman
    Department of Obstetrics and Gynecology, University Midlife Women s Health, Medical University of South Carolina, 1280 Johnnie Dodds Boulevard, Mt Pleasant, SC 29464, USA
    Semin Reprod Med 23:167-71. 2005
  2. ncbi Cancer and pregnancy
    W T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA
    Ann N Y Acad Sci 943:281-6. 2001
  3. ncbi Hormone replacement therapy after cancers
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Street, PO Box 250619, Charleston, SC 29425, USA
    Curr Opin Oncol 17:493-9. 2005
  4. doi The current status of lymphadenectomy in the management of endometrial cancer
    W T Creasman
    Medical University of South Carolina, Department of Obstetrics and Gynecology, Charleston, SC 29425, USA
    Womens Health (Lond Engl) 7:33-5. 2011
  5. ncbi Vaginal cancers
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Curr Opin Obstet Gynecol 17:71-6. 2005
  6. ncbi Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 95:593-6. 2004
  7. ncbi Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 92:525-9. 2004
  8. ncbi Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies
    Charles N Landen
    Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Boulevard, 634 CSB, Charleston, SC 29425, USA
    Am J Obstet Gynecol 188:1174-6. 2003
  9. ncbi Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
    Subbi P Mathur
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 91:486-93. 2003
  10. doi The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma
    Emma C Batchelor
    Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    Eur J Obstet Gynecol Reprod Biol 141:163-8. 2008

Detail Information

Publications20

  1. ncbi Breast cancer: the role of hormone therapy
    William T Creasman
    Department of Obstetrics and Gynecology, University Midlife Women s Health, Medical University of South Carolina, 1280 Johnnie Dodds Boulevard, Mt Pleasant, SC 29464, USA
    Semin Reprod Med 23:167-71. 2005
    ..The WHI-E only study actually notes a 23% reduction in breast cancer compared with the placebo. It would appear from a review of the literature that if there is an increased risk for breast cancer with E or E + P, it is minimal...
  2. ncbi Cancer and pregnancy
    W T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA
    Ann N Y Acad Sci 943:281-6. 2001
    ..Invasive cancer management is dependent on gestational age of the fetus. Pregnancy affords an excellent opportunity to screen for cervical neoplasia...
  3. ncbi Hormone replacement therapy after cancers
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Street, PO Box 250619, Charleston, SC 29425, USA
    Curr Opin Oncol 17:493-9. 2005
    ..With clear-cut evidence of this relation, is there evidence to suggest a role for replacement therapy in women who have been treated for endometrial cancer?..
  4. doi The current status of lymphadenectomy in the management of endometrial cancer
    W T Creasman
    Medical University of South Carolina, Department of Obstetrics and Gynecology, Charleston, SC 29425, USA
    Womens Health (Lond Engl) 7:33-5. 2011
    ..Approximately 3000 physicians from all geographic areas attended and heard presentations covering all aspects of gynecologic cancer...
  5. ncbi Vaginal cancers
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Curr Opin Obstet Gynecol 17:71-6. 2005
    ..Vaginal neoplasia is one of the rarest of malignancies. Intraepithelial lesions are usually first identified by an abnormal Pap smear in a woman without a cervix. Surgery or ablation of the epithelium is usually highly successful...
  6. ncbi Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 95:593-6. 2004
    ..The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer...
  7. ncbi Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 92:525-9. 2004
    ..To determine whether lymph vascular space involvement (LVSI) in women with early cervical carcinoma is an independent prognostic factor...
  8. ncbi Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies
    Charles N Landen
    Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Boulevard, 634 CSB, Charleston, SC 29425, USA
    Am J Obstet Gynecol 188:1174-6. 2003
    ..This study was undertaken to compare the presence of cyclooxygenase-2 (COX-2) levels between normal and malignant cervix, endometrium, and ovary...
  9. ncbi Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
    Subbi P Mathur
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Gynecol Oncol 91:486-93. 2003
    ....
  10. doi The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma
    Emma C Batchelor
    Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    Eur J Obstet Gynecol Reprod Biol 141:163-8. 2008
    ....
  11. doi Controversies surrounding lymphadenectomy and postoperative radiotherapy in the treatment of carcinoma of the endometrium
    Matthew F Kohler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
    Future Oncol 4:379-87. 2008
    ....
  12. ncbi Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]
    Subbi P Mathur
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 634, Charleston, SC 29425, USA
    Gynecol Oncol 98:467-83. 2005
    ....
  13. ncbi Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group
    Gary L Eddy
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mercer University School of Medicine, 840 Pine Street, Suite 760, Macon, GA 31201, USA
    Gynecol Oncol 106:362-9. 2007
    ..Adjuvant radiation therapy was prescribed for specific surgical/pathological risk factors for both regimens...
  14. ncbi Estrogen and cancer
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina 29412, USA
    Gynecol Oncol 86:1-9. 2002
  15. doi How valid are current cervical cancer prognostic factors that are used to recommend adjunctive radiation therapy after radical surgery?
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA
    Am J Obstet Gynecol 201:260.e1-3. 2009
    ..When the published data were evaluated, the authors' conclusions were questioned. The choice of prognostic factors does not seem appropriate based on the data that were presented...
  16. ncbi WHI: Now that the dust has settled: a commentary
    William T Creasman
    Department of Obstetrics and Gynecology, Medical University of South Carolina, USA
    Am J Obstet Gynecol 189:621-6. 2003
  17. ncbi Should symptomatic menopausal women be offered hormone therapy?
    Rogerio A Lobo
    Columbia University, Columbia University Medical Center, New York, NY, USA
    MedGenMed 8:1 p preceding 35. 2006
    ....
  18. ncbi Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
    Gynecol Oncol 84:32-5. 2002
    ..The Gynecologic Oncology Group (GOG) performed a phase II trial of PZA to determine the response rate of this agent in patients with recurrent platinum-sensitive ovarian cancer...
  19. doi History of the FIGO cancer staging system
    Franco Odicino
    Department of Obstetrics and Gynecology, Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynaecol Obstet 101:205-10. 2008
    ..This paper reviews the history of the International Federation of Gynecology and Obstetrics (FIGO) cancer staging system, how it was developed, and why...
  20. pmc Should symptomatic menopausal women be offered hormone therapy?
    Rogerio A Lobo
    Columbia University, Columbia University Medical Center, New York, NY, USA
    MedGenMed 8:40. 2006
    ....